ERBB2 and esophageal cancer: Tumors with high levels of ERBB2 amplification (>20 copies), were also significantly more common in patients with breast (7.06%) and esophageal cancers (10%) than urothelial cancers (2.93%) (p < 0.001, Supplementary Fig. 1E).